Literature DB >> 7741857

Late-acute renal allograft rejection and symptomless cytomegalovirus infection.

P Reinke1, E Fietze, S Ode-Hakim, S Prösch, J Lippert, R Ewert, H D Volk.   

Abstract

The role of cytomegalovirus infection in allograft injury is controversial. A subgroup of renal graft recipients who had histologically proven late-acute rejection did not respond to conventional anti-rejection therapy (80% graft loss within 1 year). These patients showed an expansion of memory-type CD8 peripheral-blood T cells that expressed interferon-gamma mRNA and an association with clinically symptomless cytomegalovirus infection (82% PCR positive, 42% antigenaemia). Antiviral therapy with ganciclovir resulted in stable improved graft function in 17 of 21 treated patients with cytomegalovirus-associated late-acute rejection. The results underline the clinical relevance of cytomegalovirus-related graft injury and offer a novel therapeutic approach.

Entities:  

Mesh:

Year:  1994        PMID: 7741857     DOI: 10.1016/s0140-6736(94)92887-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  22 in total

1.  Comparison of quantitative cytomegalovirus (CMV) PCR in plasma and CMV antigenemia assay: clinical utility of the prototype AMPLICOR CMV MONITOR test in transplant recipients.

Authors:  A M Caliendo; K St George; S Y Kao; J Allega; B H Tan; R LaFontaine; L Bui; C R Rinaldo
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

2.  [Intensive care treatment following transplant surgery].

Authors:  S Kohler; A Pascher; P Neuhaus
Journal:  Chirurg       Date:  2006-08       Impact factor: 0.955

3.  Allograft rejection-related gene expression in the endothelial cells of renal transplantation recipients after cytomegalovirus infection.

Authors:  Yang Li; Hang Yan; Wu-jun Xue; Pu-xun Tian; Xiao-ming Ding; Xiao-ming Pan; Xin-shun Feng; Xiao-hui Tian; He-li Xiang; Jun Hou
Journal:  J Zhejiang Univ Sci B       Date:  2009-11       Impact factor: 3.066

Review 4.  New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients.

Authors:  I G Sia; R Patel
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

5.  IL-6 induced by Staphylococcus aureus infection prevents the induction of skin allograft acceptance in mice.

Authors:  E B Ahmed; T Wang; M Daniels; M-L Alegre; A S Chong
Journal:  Am J Transplant       Date:  2011-03-30       Impact factor: 8.086

6.  Cytomegalovirus infection after intestinal transplantation in children.

Authors:  J Bueno; M Green; S Kocoshis; H Furukawa; K Abu-Elmagd; E Yunis; W Irish; S Todo; J Reyes; T E Starzl
Journal:  Clin Infect Dis       Date:  1997-11       Impact factor: 9.079

7.  Tubuloreticular Inclusions in Renal Allografts Associate with Viral Infections and Donor-Specific Antibodies.

Authors:  Michelle Willicombe; Jill Moss; Linda Moran; Paul Brookes; Eva Santos-Nunez; Adam G McLean; Thomas Cairns; David Taube; Terence H Cook; Candice Roufosse
Journal:  J Am Soc Nephrol       Date:  2015-11-27       Impact factor: 10.121

8.  Prevention of allograft tolerance by bacterial infection with Listeria monocytogenes.

Authors:  Tongmin Wang; Luqiu Chen; Emily Ahmed; Lianli Ma; Dengping Yin; Ping Zhou; Jikun Shen; Honglin Xu; Chyung-Ru Wang; Maria-Luisa Alegre; Anita S Chong
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

9.  Transplant-induced reactivation of murine cytomegalovirus immediate early gene expression is associated with recruitment of NF-κB and AP-1 to the major immediate early promoter.

Authors:  Xue-Feng Liu; Chunfa Jie; Zheng Zhang; Shixian Yan; Jiao-Jing Wang; Xueqiong Wang; Sunil Kurian; Daniel R Salomon; Michael Abecassis; Mary Hummel
Journal:  J Gen Virol       Date:  2016-01-20       Impact factor: 3.891

10.  Cytomegalovirus-infected human endothelial cells can stimulate allogeneic CD4+ memory T cells by releasing antigenic exosomes.

Authors:  Jason D Walker; Cheryl L Maier; Jordan S Pober
Journal:  J Immunol       Date:  2009-02-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.